Stocker H, Nabers A, Perna L, et al. - In this investigation, researchers studied the ability of Aβ misfolding in blood plasma, APOE4 status, and dementia risk factors to anticipate the diagnosis of Alzheimer disease (AD). In a community-based cohort, 770 candidates followed over 14 years to determine Aβ misfolding in plasma determined by immuno-infrared sensor and APOE genotype. Findings suggested an association of Aβ misfolding with a 23-fold increased odds of clinical AD diagnosis within 14 years. There was no association with the diagnosis of vascular dementia/mixed dementia. Over 14 years, APOE4-positive participants reported a 2.4-fold rise in clinical AD diagnosis. Findings suggested that Aβ misfolding in blood plasma was a strong, specific risk prediction marker for clinical AD in a community-based setting even many years prior to diagnosis.